Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon cancer from spreading, major advancements in treating colon cancer have lagged.
Jun 1, 2025
0
20
Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell lung cancer (ES-SCLC) live longer versus maintenance therapy with atezolizumab alone, according to ...
May 27, 2025
0
18
Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma. Among these, thymic carcinoma is the more aggressive subtype, characterized by high invasiveness, ...
Mar 12, 2025
0
12
Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using antihistamines in patients receiving second-line immunotherapy (IO) for bladder cancer may improve outcomes.
Feb 20, 2025
0
21
Researchers at the Icahn School of Medicine at Mount Sinai have identified the mechanism of action of a treatment for small-cell lung cancer (SCLC), one of the most aggressive and difficult-to-treat cancers. Published this ...
Dec 18, 2024
0
29
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic ...
Oct 24, 2024
0
15
The addition of the cancer immunotherapy drug atezolizumab to the standard of care concurrent chemoradiation (cCRT) did not improve overall survival for patients with limited-stage small cell lung cancer (LS-SCLC) in the ...
Sep 30, 2024
0
27
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results suggest that the timing of when ...
Sep 30, 2024
0
31
In recent years, Black patients with triple-negative breast cancer (TNBC) received immunotherapy at significantly lower rates than white patients, according to results presented at the 17th AACR Conference on the Science ...
Sep 21, 2024
1
58
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer. The results, published ...
Sep 19, 2024
0
37
